Experience with two-stage therapy in the treatment of patients with bacterial vaginosis: long-term results of treatment
- Авторлар: Rakhmatullaeva M.M.1
-
Мекемелер:
- Bukhara State Medical Institute
- Шығарылым: Том 30, № 4/5 (2023)
- Беттер: 67-71
- Бөлім: Original articles
- URL: https://journal-vniispk.ru/2073-4034/article/view/275509
- DOI: https://doi.org/10.18565/pharmateca.2023.4-5.67-71
- ID: 275509
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Тек жазылушылар үшін
Аннотация
Background. Modern principles of treatment of bacterial vaginosis (BV) include the use of complex two-stage treatment: the first stage of treatment is the eradication of opportunistic microorganisms and anaerobes; the second stage is the restoration of vaginal pH and normal microflora.
Objective. Determination of the effectiveness of different treatments for BV by assessing the composition of the vaginal microbiota.
Methods. A clinical and laboratory examination of 110 women with BV was carried out, a gynecologic history was analyzed, and the features of extragenital pathology were studied. The patients were divided into 3 groups: group I (38 patients) with severe anaerobic dysbiosis (with predominance of Gardnerella vaginalis) received metronidazole 500 mg orally 2 times a day for 7 days; group II (40 patients) with severe anaerobic dysbiosis (with predominance of obligate anaerobes) – clindamycin for 7 days; group III (32 patients) with severe aerobic-anaerobic dysbiosis – chlorhexidine for 7 days. At the 2nd stage of treatment, prebiotics or probiotics were prescribed depending on the initial number of lactobacilli. The effectiveness was evaluated 1, 3 and 6 months after the treatment, as well as upon presentation of complaints.
Results. The present study proved the importance of determining the composition and quantitative ratio of the vaginal microbiota in BV for the selection of differentiated therapy. Two-stage therapy for BV, selected taking into account the molecular biological variants of vaginal dysbiosis, had a stable treatment effect in 87.3% of cases.
Conclusion. The additional use of prebiotics of the oligosaccharide group as an anti-relapse therapy enhances the colonization of lactobacilli and ensures the stability of the vaginal biotope in 95.4% of cases.
Негізгі сөздер
Толық мәтін
##article.viewOnOriginalSite##Авторлар туралы
Mahfuza Rakhmatullaeva
Bukhara State Medical Institute
Хат алмасуға жауапты Автор.
Email: mahfuzar@inbox.ru
ORCID iD: 0000-0003-1987-6136
Cand. Sci. (Med.), Associate Professor at the Department of Obstetrics and Gynecology № 2
Өзбекстан, BukharaӘдебиет тізімі
- Voroshilina E.S., Zornikov D.L., Plotko E.E. Correction of vaginal dysbiosis with cavitated chlorhexidine solution in the first trimester of pregnancy: efficacy and safety.Zhurnal akusherstva i zhenskikh boleznei. 2014;63(5):29–37. (In Russ.).
- Zornikov D.L., Tumbinskaya L.V., Voroshilina E.S. The relationship of individual types of lactobacilli with the total share of lactoflora in the vaginal microbiocenosis and groups of opportunistic microorganisms associated with vaginal dysbiosis. Vestnik Ural’skoi meditsinskoi akademicheskoi nauki. 2015;4(55):99–105. (In Russ.).
- Kira E.F., Pekarev O.G., Molchanov O.G. et al. Comparative analysis of the efficacy and safety of parallel or sequential combination of metronidazole with lactic acid and a two-stage method of metronidazole plus probiotic. Multicenter randomized controlled trial. Obstetrics and gynecology=Akusherstvo i ginekologiya. 2016;9:87–93. (In Russ.).
- Pestrikova T.Yu., Yurasova E.A., Kotel’nikova A.V. et al. A modern approach to the treatment of recurrent bacterial vaginosis in women of the reproductive period. Ginekologiya. 2018;20(2):55–8. (In Russ.).
- Rakhmatullaeva M.M. Treatment of bacterial vaginosis: problems and prospects. Farmateka. 2019;26(6):79–83. (In Russ.). doi: 10.18565/pharmateca.2019.6.79-83.
- Selikhova M.S., Smol’yaninov A.A. New possibilities in the treatment of vaginal infections. Akusherstvo i ginekologiya: novosti mneniya, obuchenie. 2019;7(1):75–8. (In Russ.).
- Sokolova T.M., Marinkin I.O., Kuleshov V.M., Makarov K.Yu. Experience in the use of a new combination drug for the treatment of urogenital infections. Akusherstvo i ginekologiya: novosti mneniya, obuchenie. 2019;7(2):68–72. (In Russ.).
- Ashurova N.G., Rakhmatullaeva M.M., Navruzo- va N.O. The role of colposcopy in early diagnosis of the cervix. Alm Young Sci. 2018;4:21–3.
- Bradshaw C.S., Sobel J.D. Current treatment of bacterial vaginosis limitations and need for innovation. J Infect Dis. 2016;214:14–20. doi: 10.1093/infdis/jiw159.
- De Backer E., Dubreuil L., Brauman M., et al. In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis. Clin Microbiol Infect. 2010;16:470–72. doi: 10.1111/j.1469-0691.2009.02852.x.
- Lopes dos Santos Santiago G., Grob P., Verstraelen H., et al. Susceptibility testing of Atopobium vaginae for dequalinium chloride. BMC. Res Notes. 2012;19(5):151. doi: 10.1186/1756- 0500-5-151.
- Rakhmatullaeva M.M. Clinical and epidemiological features of bacterial vaginosis. Am J Med Sci Pharm Res. 2020;02(8):140–45.
Қосымша файлдар
